Ovarian cancer patients get immune boost in new drug trial
NCT ID NCT02726997
First seen Nov 10, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This early-phase study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy helps women with advanced ovarian, fallopian tube, or primary peritoneal cancer. 18 participants received the combination to see how it affects the immune system and tumor growth. The goal is to find better ways to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III OVARIAN CANCER AJCC V6 AND V7 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.